08:30-10:00	The End of Preimplantation Genetic Screening (PGS) or Only the Beginning?
Capsule	Preimplantation genetic diagnosis (PGD) was initially introduced to identify single gene defects, but evolved under the acronym “PGS” (preimplantation genetic screening) into a tool to detect embryo aneuploidy. The proposed goal was to improve pregnancy rates in IVF, and reduce spontaneous abortion rates, but so far studies have failed to prove the concept. The question now is whether we should declare that the introduction of PGS for these indications is one of the major ART-related failures, and discontinue the practice completely, or should we keep refining the technique, using newer technologies such as comparative genomic hybridization (CGH), and later embryo diagnosis via trophectoderm biopsy
Chairpersons	Z. Shoham, Israel K. Diedrich, Germany
	Debate: PGS is an Experimental Tool that should be Banned from Routine Clinical Use!     Proposition: PGS, as currently practiced, is associated with inferior results and should not be routinely offered N. Gleicher, USA Opposition: The beneficial effects of preimplantation genetic diagnosis for aneuploidy support extensive clinical applications A.G. Schmutzler, Germany Discussion
	Polar body array CGH prediction of embryo ploidy: Is this the future of IVF? S. Fishel, UK
Objectives	Upon completion of this debate, the audience will learn:
	* The hypothesis that makes PGS an attractive proposition * Reasons why PGS, as performed, failed to meet expectations * New technologies and techniques, which, potentially, may positively affect PGS results * What the IVF field, in general, can learn from the PGS experience * Learn about CGH and its role in future PGS
10:00-10:20	Coffee break

10:20-11:50	SPRM's- New Player in the Treatment of Uterine Fibroids! Sponsored by an unrestricted grant from PregLem SA
Capsule	New class of oral drugs called specific progesterone receptors modulators (SPRM's), promises to diversify medical treatment choice for uterine fibroids. Will it change the surgical management of uterine fibroids?
Chairpersons	Z. Ben-Rafael, Israel B.C.J.M.  Fauser, Netherlands
Introduction	Personal story of woman suffering from Symptomatic Uterine Fibroids
	Where do we stand today? A clinician’s perspective H.C.H.R. Tinneberg, Germany
	Are SPRM's an answer to Uterine Fibroids? B.C.J.M. Fauser, Netherlands
	Debate: Counter Views: Should we consider SPRM’s as the first treatment of choice for symptomatic uterine fibroids?   A Gyne-Surgeon Point of View: Is there a room for pre-operative SPRM treatment for uterine fibroid surgery? J. Donnez, Belgium A Gyne-Endocrinologist Point of View: Can intermittent long-term use of SPRM impact surgical decisions? P. Bouchard, France General Discussion
Objectives	To acquire knowledge about the following:
	* The gaps between the treatment choices and patient's needs * The mechanism of action of newer drugs-SPRM's * The possible clinical usage of SPRM’s * The clinical expectations and results from SPRM's for uterine fibroids
11:50-12:10	Poster viewing
12:10-13:40	Join Hall A or B
13:40-14:30	Lunch break

14:30-16:00	Assessment and Treatment of Ovarian Reserve
Capsule	Diminished ovarian reserve (DOR) remains a common, frustrating and underdiagnosed condition. Lack of criteria for diagnosis makes it difficult to assess and compare prevalence of diagnosis and results of treatments. Indeed, questions have been raised as to whether DOR even lends itself to treatment and, if so, whether treatment regimen results differ
Chairpersons	S. Daya, Canada R. Frydman, France
	Debate: Has Anti-Müllerian Hormone (AMH) become Essential in Assessing Ovarian Reserve? Yes: P. Bouchard, France invitation sent No: N. Gleicher, USA Discussion
	Debate: Can Diminished Ovarian Reserve be Treated Effectively? Yes: N. Gleicher, USA  No: P. Patrizio, USA Discussion
Objectives	Upon completion of these debates, the audience will have learned the following:
	* How DOR is defined in the literature * Why age-specific ovarian reserve determination improves sensitivity of diagnosis of DOR * The best methodologies for diagnosing DOR * Whether DOR lends itself to treatment
16:00-16:30	Coffee break

16:30-18:00	Hot Controversial Topics in ART  Round Table Discussion
Chairpersons	Z. Ben Rafael, Israel B.C.J.M. Fauser, Netherlands
Discussants	R. Frydman, France P. Patrizio, USA N. Gleicher, USA S. Daya, Canada A. Pellicer, Spain
	Experts’ opinions and audience interaction
	Should we remove intramural fibroid of 3-5 cm after two failed IVF? Should endometrioma be excised before ART? IVF in endometriosis: Regular or extended (3-month) down regulation? Routine Metformin for PCO with high BMI, what are the evidence? Should we be satisfy with one insemination (18h or 36h after HCG) Based on recent publication? Cheaper IVF: How can this be achieved? Should tests of ovarian reserve be routinely performed? What is the gain? How can we  individualize the FSH starting dose before ovarian stimulation for IVF? How can ET be improved? Immunoglobulin for Recurrent pregnancy loses; the end?

Saturday, November 6, 2010

08:30-10:00	Mild Stimulation for IVF Organized and supported by The International Society for Mild Approaches in Assisted Reproduction (ISMAAR)
Capsule	Proponents of mild IVF claim that this is the way for ART especially in an era of single embryo transfer. IVM technology is the real "Mild" alternative. Can we agree on what the future holds?
Chairpersons	B.C.J.M. Fauser, Netherlands
	Debate: Mild IVF or IVM What Direction should We Take? Proposition: Mild IVF is the way to go R. Frydman, France Opposition: IVM is the alternative to IVF T. Child, UK Discussion
	Which patient can benefit from Natural/modified natural cycle IVF? R. Frydman, France
Objectives	To acquire knowledge about the following:
	* What is “mild” stimulation and what are its advantages and disadvantages * Which patients are the most likely candidates for such stimulation * Arguments for and against IVM without stimulation
13:40-14:30	Lunch break

10:20-11:50	Laboratory Techniques Round Table Discussion
Capsule	How to improve efficiency in order to avoid mistakes in an IVF laboratory
Chairpersons	S. Fishel, UK R. Frydman, France
Discussants	G. Calderon, Spain A. Arav, Israel L. Jenner, UK T. Child, UK Y. Barak, Israel
	Laboratory experts’ opinions and audience interaction on basic aspects of laboratory work in ART:
	How to avoid mistakes in an IVF laboratory Electronic witnessing: Pros, cons, bar coding and RFIDs Oocytes and embryo markers of viability Simplified-IVF approaches: Are they evidence-based? Selecting the best embryos: Genomics, proteomics and time-laps? Vitrification vs slow freezing Vitrification: Has it killed the need for expensive freezing machines? Vitrification: Heralded the era of successful egg freezing for medical therapy and social liberation Oocyte freezing: Are babies born healthy?
Objectives	Upon completion of this session, the audience will acquire:
	* Strategies for minimizing risk, especially that of mixed-up/mixed gametes and ET * Strategies for robust, reliable, informative and  objective markers of oocyte and embryo viability * Strategies for optimizing cost-effective cryopreservation of oocytes and embryos
11:50-12:10	Poster viewing

12:10-13:40	In-Vitro Maturation (IVM)
Capsule	IVM is becoming more effective: Benefits, risk and pitfalls of the procedure
Chairperson	Z. Shoham, Israel L. Kiesel, Germany
	Debate: Will IVM Ever Replace Standard IVF? Yes: Results of IVM are comparable to standard IVF with or without stimulation T. Child, UK No: IVM does not offer any advantage over current IVF practice K.R. Held, Germany Discussion
	IVM as an alternative for poor and over-responders, PCO, frozen immature eggs T. Child, UK
Objectives	Upon completion of this session, the audience will have acquired:
	* Understanding of the place of IVM in comparison to IVF * Understanding of the laboratory procedures * Understanding of the best preparation and aspiration procedures * Special indications for IVM
10:00-10:20	Coffee break

14:30-16:00	Endometriosis During Reproductive Years
Capsule	Poor correlation between clinical stages of endometriosis and symptoms, pain and infertility, makes it difficult to assess the results of therapy. The limited understanding of the pathophysiology of this enigmatic condition creates a real need to frequently scrutinize the working theory and to tailor the treatment to the patient’s needs
Chairperson	V. Gomel, Canada A. Schultze-Mosgau, Germany
	Debate: Which Treatment Offers Longstanding Remission for Chronic Pelvic Pain in Young Women with Endometriosis       Proposition: Surgery with preservation of fertility is the treatment of choice J. Donnez, Belgium   Opposition: Medical treatment can preserve fertility without the burden of surgery D. Hornung, Germany Discussion
	How to reduce postsurgical adhesion in endometriosis P. Koninckx, Belgium
Objectives	Upon completion of this session, the audience will have acquired knowledge about the following:
	* Correlation between stages of infertility and endometriosis * How and when to choose between available treatments * Reasons, risks and prevention of surgically-induced adhesion
16:00-16:30	Coffee break

16:30-18:00	Differences in Regulations of ART
Capsule	Regulation can be as constraining as it is hoped to be supportive in the provision of an ‘ethical’ framework. Without regulation of any kind, bad practice can escalate and become the norm. With regulation, excessive strictures can reduce, or even inhibit some patients’ opportunities, whilst compelling others to travel abroad for treatment – often to countries without rules. Among the many known instances is also the example of egg donations. Limitations on payment in some countries, combined with donors being identifiable, have also resulted in many recipients traveling annually to other countries. Can a balance be found to encourage a sufficient supply of donated eggs so that donors and recipients can be treated closer to home in a safe, regulated environment?
Chairpersons	V. Gomel, Canada N. Gleicher USA
	Strict regulation limits patient choice, as well as results of treatment! K. Diedrich, Germany
	Debate: Should Egg Donors Receive Payment or Only a Modest Sum with Receipts for Necessary Expenses?          Pros: Egg donation should be an act of altruism irrespective of the effects on supply D. Hamm, UK   Cons: Egg donors should involve incentive to the donor - in line with current regulations in some countries A. Pellicer, Spain Discussion
Objectives	To acquire knowledge regarding the following:
	* Current situation in several different countries with contrasting regulations * The debate on funding egg donors * Understanding the ethical dimension, such that there are different dimensions packaged as ‘ethics’ * The real problems faced by recipients * The importance of egg donation as a treatment option * Limitations on free choice of patients and physicians by current regulation

Sunday, November 7, 2010

08:30-10:00	Polycystic Ovarian Syndrome (PCOS)
Capsule	As the relationships among PCOS glucose intolerance, insulin resistance, obesity and metabolic syndrome are deciphered, the need for the gynecologist to be updated increases. The question is when PCOS starts, what the lomg term risks are, and should we treat all PCOS patients, The role played by the primary gynecologist in limiting this very common endocrinopathy is of prime interest for patients and physicians alike!
Chairperson	P. Patrizio, USA R. Fischer, Germany
	Pediatric origin of adult PCOS C. Sultan, France
	Debate: Should all infertile patients be tested for glucose intolerance and should Metformin be Routinely Used in PCOS? Pros: All PCOS patients should be tested, and Metformin use can improves pregnancy outcome S. Daya, Canada Cons: Patients should be tested by indication; systemic review does not show consistent effect of Metformin on PCOS patients! P. Bouchard, France Discussion
	What proofs do we, or do we not have for the long-term risks of PCOS women? B.C.J.M. Fauser, Netherlands
Objectives	Upon completion of this debate, the audience will have learn:
	* When does PCOS starts * About the risk for glucose intolerance in PCOS patients * Whether we should actively look for diabetes in asymptomatic patients * Which tests are the most appropriate * Long term ill-effects of PCOS
10:00-10:30	Coffee break

10:30-12:30	New Cryotechnologies for Gametes, Ovarian Tissue and Stem Cells
Capsule	The optimum method for cryopreserving oocytes and ovarian tissue is yet to be decided; exploring new cryopreservation technologies can diversify the choice and enhance clinical efficiency
Chairperson	A. Arav, Israel J. Donnez, Belgium C.Q.  Zhou, China
	Counter-views / Debate: Preservation of Fertility: What can we Offer? Autotransplantation of fresh or frozen human ovarian tissue? Freezing a whole ovary cortex or others? J. Donnez, Belgium P. Patrizio, USA Discussion
	Freeze/drying of spermatozoa or stem cells: What are the advantages and pitfalls? A. Arav, Israel
	Multipotent adult germ line stem cells: New therapeutic hope? K. Guan, Germany